

PRESS RELEASE

Change in number of shares and votes in Camurus

Lund, Sweden — 31 January 2024 — As previously announced, Camurus has carried out a directed share issue. The directed share issue has resulted in a change in the number of shares and votes in Camurus as follows:

Prior to the directed share issue, the total number of shares in Camurus amounted to 55,623,618, corresponding to 55,623,618 votes. The number of shares and votes has as a result of the directed share issue increased by 2,000,000 shares and votes. As of 31 January 2024, the total number of shares in Camurus amounts to 57,623,618, corresponding to 57,623,618 votes.

For more information

Fredrik Tiberg, President & CEO

Tel. +46 (0)46 286 46 92

fredrik.tiberg@camurus.com

Fredrik Joabsson, Chief Business Development Officer

Tel. +46 (0)70 776 17 37

ir@camurus.com

About Camurus

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

This information is information that Camurus AB is obliged to make public pursuant to Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act. The information was submitted for publication at 7.00 am CET on 31 January 2024.